Cipla Limited (BSE: 500087) (NSE: CIPLA-EQ) (hereafter referred to as 'Cipla') and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as 'Cipla'), today announced that it has received ...

Mumbai/Warren: Cipla is sharpening its position in the U.S. respiratory segment with a key regulatory win that opens up a ...

Cipla Ltd has gained final USFDA approval for its generic albuterol sulfate inhalation aerosol, used to treat bronchospasm. This approval highlights Cipla’s expertise in inhalation products and marks ...

A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...

The product is expected to be launched in the United States in the first half of FY27. According to IQVIA data, the US market ...

Launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosolBRIDGEWATER, N.J., April 14, 2026 (GLOBE ...

Starting January 1, a drug that thousands of patients depend on to help them breathe will disappear from pharmacy shelves, and doctors are concerned patients may have delays switching to alternatives ...

Add Yahoo as a preferred source to see more of our stories on Google. One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially ...

WASHINGTON The Food and Drug Administration today issued a public health advisory to alert patients, caregivers and healthcare professionals to switch to hydrofluoroalkane propelled albuterol inhalers ...

Starting January 1, a drug that thousands of patients depend on to help them breathe will disappear from pharmacy shelves, and doctors are concerned patients may have delays switching to alternatives ...